A detailed history of Israel Englander (Millennium Management LLC) transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 3,135,317 shares of TSHA stock, worth $10.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,135,317
Previous 50,000 6170.63%
Holding current value
$10.8 Million
Previous $88,000 10125.0%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$1.43 - $3.25 $350,657 - $796,948
-245,215 Reduced 7.25%
3,135,317 $9 Million
Q4 2023

Feb 14, 2024

BUY
$1.33 - $2.88 $3.68 Million - $7.96 Million
2,765,594 Added 449.74%
3,380,532 $5.98 Million
Q2 2023

Aug 14, 2023

BUY
$0.59 - $0.87 $81,356 - $119,966
137,893 Added 28.91%
614,938 $405,000
Q1 2023

May 15, 2023

BUY
$0.65 - $2.3 $58,796 - $208,048
90,456 Added 23.4%
477,045 $380,000
Q4 2022

Feb 14, 2023

BUY
$1.89 - $2.44 $401,078 - $517,794
212,211 Added 121.7%
386,589 $874,000
Q3 2022

Nov 14, 2022

SELL
$1.89 - $4.94 $78,983 - $206,442
-41,790 Reduced 19.33%
174,378 $337,000
Q2 2022

Aug 15, 2022

BUY
$2.47 - $6.77 $533,934 - $1.46 Million
216,168 New
216,168 $804,000
Q1 2022

May 16, 2022

SELL
$5.22 - $11.86 $313,455 - $712,181
-60,049 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$11.43 - $19.2 $686,360 - $1.15 Million
60,049 New
60,049 $700,000
Q3 2021

Nov 15, 2021

SELL
$15.82 - $21.57 $477,210 - $650,659
-30,165 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$19.29 - $26.38 $174,381 - $238,475
9,040 Added 42.79%
30,165 $639,000
Q1 2021

May 17, 2021

BUY
$20.3 - $31.75 $35,017 - $54,768
1,725 Added 8.89%
21,125 $429,000
Q4 2020

Feb 16, 2021

SELL
$19.14 - $28.13 $2.94 Million - $4.33 Million
-153,857 Reduced 88.8%
19,400 $515,000
Q3 2020

Nov 16, 2020

BUY
$22.4 - $24.47 $3.88 Million - $4.24 Million
173,257 New
173,257 $3.88 Million

Others Institutions Holding TSHA

About Taysha Gene Therapies, Inc.


  • Ticker TSHA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,359,500
  • Market Cap $166M
  • Description
  • Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...
More about TSHA
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.